Zhu G, Chen H, Liu S, Lin P, Lin C, Ye J
Sci Rep. 2025; 15(1):6160.
PMID: 39979355
PMC: 11842632.
DOI: 10.1038/s41598-025-89519-7.
Zhou X, Wu J, Liu Y, Wang X, Gao X, Xia X
J Cancer. 2025; 16(4):1243-1263.
PMID: 39895799
PMC: 11786036.
DOI: 10.7150/jca.104424.
Gurau A, Monton O, Greer J, Johnston F
J Surg Res. 2024; 304:196-206.
PMID: 39551014
PMC: 11645221.
DOI: 10.1016/j.jss.2024.10.014.
Flemming S, Kollmann L, Widder A, Backhaus J, Lock J, Nickel F
Langenbecks Arch Surg. 2024; 409(1):299.
PMID: 39377929
PMC: 11461774.
DOI: 10.1007/s00423-024-03485-8.
Liu Z, Sun L, Zhu W, Zhu J, Wu C, Peng X
Biol Direct. 2024; 19(1):65.
PMID: 39148138
PMC: 11325698.
DOI: 10.1186/s13062-024-00518-6.
The cGAS/STING Pathway-A New Potential Biotherapeutic Target for Gastric Cancer?.
Tian M, Zhang S, Tan F
J Pers Med. 2024; 14(7).
PMID: 39063990
PMC: 11277918.
DOI: 10.3390/jpm14070736.
Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: a systematic review and meta-analysis.
Guchelaar N, Nasserinejad K, Mostert B, Koolen S, van der Sluis P, Lagarde S
Br J Surg. 2024; 111(5).
PMID: 38722803
PMC: 11081074.
DOI: 10.1093/bjs/znae116.
Liquid biopsy for gastric cancer: Techniques, applications, and future directions.
Diaz Del Arco C, Fernandez Acenero M, Ortega Medina L
World J Gastroenterol. 2024; 30(12):1680-1705.
PMID: 38617733
PMC: 11008373.
DOI: 10.3748/wjg.v30.i12.1680.
Comparison of the Prognosis of Upper-Third Gastric Cancer With That of Middle and Lower-Third Gastric Cancer.
Park J, Kim E, Yang J, Park K, Kwon O
J Gastric Cancer. 2024; 24(2):159-171.
PMID: 38575509
PMC: 10995826.
DOI: 10.5230/jgc.2024.24.e3.
Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration.
Diaz Del Arco C, Fernandez Acenero M, Ortega Medina L
Int J Mol Sci. 2024; 25(5).
PMID: 38473896
PMC: 10931799.
DOI: 10.3390/ijms25052649.
Mutational landscape of TP53 and CDH1 in gastric cancer.
Cai H, Zhang L, Fu L, Xu B, Jiao Y
World J Gastrointest Surg. 2024; 16(2):276-283.
PMID: 38463349
PMC: 10921187.
DOI: 10.4240/wjgs.v16.i2.276.
Population-based X-ray gastric cancer screening in Hiroshima prefecture, Japan.
Vu N, Urabe Y, Quach D, Oka S, Hiyama T
World J Clin Oncol. 2024; 15(2):271-281.
PMID: 38455140
PMC: 10915947.
DOI: 10.5306/wjco.v15.i2.271.
Immune checkpoint inhibitors or anti-claudin 18.2 antibodies? A network meta-analysis for the optimized first-line therapy of HER2-negative gastric cancer.
Zhang Z, Xie T, Wang Y, Shen L, Zhang X, Peng Z
Ther Adv Med Oncol. 2024; 16:17588359241231253.
PMID: 38362378
PMC: 10868489.
DOI: 10.1177/17588359241231253.
Clinical significance of sarcopenia in patients undergoing treatment for gastric cancer.
Ozcan S, Kacan T, Kacmaz N, Gundogan B, Vurgec I, Ozyildirim S
Rev Assoc Med Bras (1992). 2023; 69(12):e20230568.
PMID: 37971119
PMC: 10645170.
DOI: 10.1590/1806-9282.20230568.
Surgical Techniques and Related Perioperative Outcomes After Robot-assisted Minimally Invasive Gastrectomy (RAMIG): Results From the Prospective Multicenter International Ugira Gastric Registry.
de Jongh C, Cianchi F, Kinoshita T, Kingma F, Piccoli M, Dubecz A
Ann Surg. 2023; 280(1):98-107.
PMID: 37922237
PMC: 11161237.
DOI: 10.1097/SLA.0000000000006147.
CYP19A1 promotes gastric cancer as part of a lipid metabolism-related gene signature related to the response of immunotherapy and prognosis.
Zhou X, Meng F, Xiao L, Shen H
BMC Med Genomics. 2023; 16(1):228.
PMID: 37784135
PMC: 10544546.
DOI: 10.1186/s12920-023-01664-y.
The influence of partial gastrectomy for gastric cancer on the spontaneous disappearance of Helicobacter pylori: A single-center prospective study.
Yanagawa S, Fujikuni N, Tanabe K, Nakahara M, Noriyuki T
Cancer Rep (Hoboken). 2023; 6(12):e1903.
PMID: 37697944
PMC: 10728519.
DOI: 10.1002/cnr2.1903.
Impact of Age at Diagnosis on Clinicopathological Features, Prognosis, and Management of Gastric Cancer: A Retrospective Single-Center Experience from Spain.
Diaz Del Arco C, Ortega Medina L, Estrada Munoz L, Molina Roldan E, Garcia Gomez de Las Heras S, Fernandez Acenero M
Cancers (Basel). 2023; 15(17).
PMID: 37686517
PMC: 10486869.
DOI: 10.3390/cancers15174241.
An immunogenic cell death-related signature predicts prognosis and immunotherapy response in stomach adenocarcinoma.
Liu Z, Sun L, Peng X, Liu S, Zhu Z, Huang C
Apoptosis. 2023; 28(11-12):1564-1583.
PMID: 37580435
DOI: 10.1007/s10495-023-01879-5.
PFDN2 promotes cell cycle progression via the hnRNPD-MYBL2 axis in gastric cancer.
He Q, Ding Z, Chen T, Wu H, Song J, Xiang Z
Front Oncol. 2023; 13:1164070.
PMID: 37538116
PMC: 10395514.
DOI: 10.3389/fonc.2023.1164070.